An interventional study of ARssist and ARport system in Prostate Cancer, sponsored by Chinese University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Chinese University of Hong Kong · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Prostatic Neoplasms by Chinese University of Hong Kong — 15 open to participants now, 17 under way, none of them phase 3. Prostatic Neoplasms · Chinese University of Hong Kong.
Among the 37 studies in Prostatic Neoplasms by Chinese University of Hong Kong, this one is the 14th largest by planned enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2026, is one of 18 with no phase, reaches primary completion later than 13 of the 16 other live ones, and was the 37th registered.
7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →15 of the 37 studies in Prostatic Neoplasms by Chinese University of Hong Kong are open now, in 2 countries. Recruiting first, the newest first:
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18+ · Men only
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18+ · Men only
Chinese University of Hong Kong · Sites in Hong Kong
Ages 40–85 · Men only
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18+ · Men only
Chinese University of Hong Kong · Sites in China
Ages 18–80
By country, each count listing its studies:
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 71 across the 20 interventional studies, 300 across the 17 observational. Of the 16 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Chinese University of Hong Kong is the lead sponsor of 1,458 studies on the registry; 478 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
5 of the studies in Prostatic Neoplasms by Chinese University of Hong Kong that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06303622Chinese University of Hong KongComparing MRI-Ultrasound Fusion and Cognitive-guided Biopsy for the Detection of csPCa: the PROFUSION Trial | 2026-12-31 |
| NCT07057375Chinese University of Hong KongThe Effect of Pulsed Electromagnetic Field Therapy on Muscle Mass and Muscle Strength in Prostate Cancer Patients Treated With Androgen Deprivation Therapy | 2026-12-31 |
| NCT02339701Chinese University of Hong KongStereotactic Body Radiotherapy vs Intensity-modulated Radiotherapy in Prostate Cancer | 2026-12-31 |
| NCT06886321Chinese University of Hong KongProstate Irreversible Electroporation Study | 2027-01-31 |
| NCT06926374Chinese University of Hong KongProspective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic Surgery | 2027-04 |
Add all 5 to your calendar (.ics) → With an account.
Among the 37 studies in Prostatic Neoplasms by Chinese University of Hong Kong, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Robotic prostatectomy is a surgery for treating localized prostate cancer. The ARssist \& ARport system is a novel augmented reality system designed for the assistant surgeon, allowing delivery of augmented reality information. This study aims at evaluating the safety and feasibility of the use of ARssist \& ARport system in robotic prostatectomy.
This is a prospective study to evaluate the clinical feasibility and safety of the ARssist and ARport system during robotic surgery with Robotic surgical System. During the operation, the assistant surgeon will utilize the ARssist \& ARport system to assist the chief surgeon. Subjects will receive standard post-operative care. The primary objective of this study is to demonstrate the safety and clinical feasibility of the ARssist and ARport system in helping the patient side surgeon perform laparoscopic tasks during robotic assisted urological surgeries, with primary endpoints being safety data and complications.
Patient Inclusion Criteria
Patient Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: ARssist and ARport system
The surgery will follow the same steps of a standard robotic assisted radical prostatectomy procedure, with the addition of the ARssist and/or ARport system used by the patient side surgeon.
Number of intervention-related surgical complication
All post-operative complications within 30 days. Complications will be classified based on the Clavien-Dindo classification of surgical complications
Time frame: On Day 30
Performance of the patient side surgeon
By Global Operative Assessment of Laparoscopic Skills( GOALS) checklist, a 5-item global rating scale scored on a 5-point scale, the higher mark reflect the better performance
Time frame: Perioperative
Specific feedback on the use of the system by patient side surgeon
A customized questionnaire of 10 items on a 5-point Likert scale ; the items included are selected and adopted from the feedback questionnaire designed for a study on HoloLens use in ureteroscopic procedure; by a System Usability Scale; the NASA Task Load Index and the Simulator sickness questionnaire. The higher the marks reflect the better performance
Time frame: Perioperative
Operative Time
The duration of operation
Time frame: Perioperative
Blood Loss
The total amount of blood loss in the operation in ml
Time frame: Perioperative
Hospital Stay
Duration of hospital stay in days
Time frame: Perioperative
Plan to share: No
Started Nov 2026 (actual). Primary completion is estimated for Jun 2029, 31 months after the start.
Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 31 months is below that.
Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chinese University of Hong Kong →